Cardiol Therapeutics INc.

CRDL-T

Analysis and Opinions about CRDL-T

Signal
Opinion
Expert
BUY
BUY
April 24, 2020
COVID-19 heart issues? The company makes a synthetic CBD. Their original work saw CBD helped to reduce inflammation of the heart. It is expected they will start to re-purpose their product for COVID patients. This would help accelerate testing by about 2 years. This could lead to product being sold in Canada very quickly. A great opportunity.
Show full opinionHide full opinion
COVID-19 heart issues? The company makes a synthetic CBD. Their original work saw CBD helped to reduce inflammation of the heart. It is expected they will start to re-purpose their product for COVID patients. This would help accelerate testing by about 2 years. This could lead to product being sold in Canada very quickly. A great opportunity.
COMMENT
COMMENT
March 18, 2019
They struck a deal with Noramco, to sell into Canada and Mexico, synthetic CPD (for heart medication). They have enough cash to self finance the heart research.
Show full opinionHide full opinion
They struck a deal with Noramco, to sell into Canada and Mexico, synthetic CPD (for heart medication). They have enough cash to self finance the heart research.
HOLD
HOLD
February 15, 2019
He has met management twice and they had their IPO in mid-December. They have looked into the use of CBD to use as an anti-inflammatory for heart patients. They are working on developing synthetic CBD. They think they could produce 1 millions grams of CBD this year. This creates a great opportunity and they have enough technology to advance their strategy. If they can sell the CBC, the company is fairly valued.
Show full opinionHide full opinion
He has met management twice and they had their IPO in mid-December. They have looked into the use of CBD to use as an anti-inflammatory for heart patients. They are working on developing synthetic CBD. They think they could produce 1 millions grams of CBD this year. This creates a great opportunity and they have enough technology to advance their strategy. If they can sell the CBC, the company is fairly valued.
Showing 1 to 3 of 3 entries
  • «
  • 1
  • »

Cardiol Therapeutics INc.(CRDL-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Cardiol Therapeutics INc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Cardiol Therapeutics INc.(CRDL-T) Frequently Asked Questions

What is Cardiol Therapeutics INc. stock symbol?

Cardiol Therapeutics INc. is a Canadian stock, trading under the symbol CRDL-T on the Toronto Stock Exchange (CRDL-CT). It is usually referred to as TSX:CRDL or CRDL-T

Is Cardiol Therapeutics INc. a buy or a sell?

In the last year, 1 stock analyst published opinions about CRDL-T. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Cardiol Therapeutics INc..

Is Cardiol Therapeutics INc. a good investment or a top pick?

Cardiol Therapeutics INc. was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Cardiol Therapeutics INc..

Why is Cardiol Therapeutics INc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Cardiol Therapeutics INc. worth watching?

1 stock analyst on Stockchase covered Cardiol Therapeutics INc. In the last year. It is a trending stock that is worth watching.

What is Cardiol Therapeutics INc. stock price?

On 2020-09-30, Cardiol Therapeutics INc. (CRDL-T) stock closed at a price of $3.05.